AV2 DM
Alternative Names: AV2-DMLatest Information Update: 13 Aug 2015
Price :
$50 *
At a glance
- Originator Cesa Projects International
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 13 Aug 2015 No recent reports on development identified - Phase-II for Human papillomavirus infections in Belgium (Topical)
- 08 Nov 2012 Cesa Projects International completes enrolment in its phase II trial for Human papillomavirus infections in Belgium (NCT01654822)
- 01 Aug 2012 Phase-II clinical trials in Human papillomavirus infections in Belgium (Topical)